<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04063358</url>
  </required_header>
  <id_info>
    <org_study_id>SecondMMU2019</org_study_id>
    <nct_id>NCT04063358</nct_id>
  </id_info>
  <brief_title>Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery</brief_title>
  <acronym>Anti-VEGF</acronym>
  <official_title>Timing of Anti-vascular Endothelial Growth Factor（Anti-VEGF） Intravitreous Injections for Diabetic Macular Edema(DME) in Patients Undergoing Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Military Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to evaluate how different timing of anti-VEGF intravitreous injections
      affect visual acuity (BCVA) in patients with diabetic macular edema who are undergoing
      cataract surgery; and to evaluate how different timing of anti-VEGF intravitreous affect OCT
      CSF thickness and total number of postoperative injections in patients with diabetic macular
      edema who are undergoing cataract surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cataract is very common in diabetic patients and can lead to significant vision loss and
      disability without medical intervention. Diabetic patients, particularly those with diabetic
      macular edema (DME), experience poorer visual outcomes after undergoing cataract surgery
      compared to non-diabetics. An increased risk in the development of post-operative cystoid
      macular edema and exacerbation of baseline DME is reported and this poses a significant
      challenge in managing concomitant DME and visually-significant cataracts.

      Goals of the study are to evaluate how different timing of anti-VEGF intravitreous injections
      (before operation, intra-operation or after-operation) affect visual acuity (BCVA) in
      patients with persistent diabetic macular edema who are undergoing cataract surgery; and to
      evaluate how different timing of anti-VEGF intravitreous injections affect OCT CSF thickness
      and total number of postoperative injections in patients with diabetic macular edema who are
      undergoing cataract surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in best-corrected visual acuity (BCVA)</measure>
    <time_frame>1 month, 3 months , 6 months and 12 months after cataract surgery</time_frame>
    <description>BCVA is a measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if uncorrected eyesight is 20/200, but patient can see 20/20 with glasses, the BCVA is 20/20.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in optical coherence tomography (OCT) central subfield (CSF) thickness</measure>
    <time_frame>24 hours post-operatively, 1 month, 3 months , 6 months and 12 months after cataract surgery</time_frame>
    <description>Optical coherence tomography (OCT) is an important imaging modality in the evaluation and management of retinal diseases. Change in central subfield (CSF) thickness will be measured and recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of postoperative injections</measure>
    <time_frame>12 months after cataract surgery</time_frame>
    <description>Total number of postoperative injections will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of patients with diabetic retinopathy progression</measure>
    <time_frame>12 months after cataract surgery</time_frame>
    <description>patients with diabetic retinopathy progression will be calculated</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Lucentis injected Pre-operatively</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lucentis injected 2 weeks before cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lucentis injected intra-operatively</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lucentis injected during the course of the surgery by cataract surgeon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lucentis injected post-operatively</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lucentis injected 2 weeks after cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis</intervention_name>
    <description>Lucentis 0.5 MG Per 0.05 ML Injection</description>
    <arm_group_label>Lucentis injected Pre-operatively</arm_group_label>
    <arm_group_label>Lucentis injected intra-operatively</arm_group_label>
    <arm_group_label>Lucentis injected post-operatively</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adults over age 18 with diabetes mellitus, diabetic macular edema and visually significant
        cataracts planning to undergo cataract surgery

        Exclusion Criteria:

        Patients who have undergone panretinal photocoagulation (PRP) in prior 4 months or an
        ocular condition (other than cataract and DME) that might affect visual acuity during
        course of study.

        Patients with history of vitrectomy. Patients with neovascular glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>wei shen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>dongyan pan</last_name>
    <phone>86-21-31161995</phone>
    <email>campus@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>wei shen</last_name>
    <phone>86-21-31161995</phone>
    <email>shenwzz@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>86-21</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>dongyan pan</last_name>
      <phone>86-21-31161995</phone>
      <email>campus@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2019</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Second Military Medical University</investigator_affiliation>
    <investigator_full_name>pandongyan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

